skraler.bsky.social
Simon Kraler
@skraler.bsky.social
20 followers 42 following 2 posts
MD PhD. Prefer climbing to football, cycling to walking, Kinks to Stones. Cardiologist, scientist, editor @EJCI & editorial-board member @EHJ.
Posts Media Videos Starter Packs
skraler.bsky.social
Simon Kraler @skraler.bsky.social · Aug 28
#ESCCongress 2025 #Global #Health 🇪🇸

Proud to be a #Social #Media #Ambassador for #Acute #Coronary #Syndromes & #CAD – sharing the latest science 🌍Excited to work w/ @drmilicaa @franciscojlk @rafavidalperez @liberale_luca and all other amazing colleagues👇

#CVHealthForAll❤️
escardio.bsky.social
European Society of Cardiology @escardio.bsky.social · Aug 28
🎉 The wait is almost over! #ESCCongress kicks off tomorrow!

Meet our amazing Social Media Ambassadors 🙌
Follow their journey, join the conversation, and catch the hottest updates & highlights straight from Madrid!💙
1 2
Reposted by Simon Kraler
stefaniedimmeler.bsky.social
Stefanie Dimmeler @stefaniedimmeler.bsky.social · Aug 4
🚨 Excited to share that our latest study on the role of inflammatory activation in endothelial cells during the infarct response is now published in Circulation Research!

Huge thanks to all co-authors—especially Lukas, Till, Simone, and Ariane—for driving this project forward.
1 5 12
Reposted by Simon Kraler
appliedcvb.bsky.social
ISACB @appliedcvb.bsky.social · Jun 23
Member publication alert:

Vascular (dys)function in the failing heart

www.nature.com/articles/s41...
Vascular (dys)function in the failing heart - Nature Reviews Cardiology
Coronary and systemic vascular dysfunction contributes to the initiation and progression of heart failure (HF) with or without reduced ejection fraction and, vice versa, HF compromises vascular functi...
www.nature.com
1 1
skraler.bsky.social
Simon Kraler @skraler.bsky.social · May 14
🚨 Now up
@escardio.bsky.social

Acute coronary syndromes: together w/
@dlbhattmd.bsky.social, C Mueller & P Libby we call for a precision medicine approach

🔹 Diverse mechanisms
🔹 Sex-specific differences
🔹 Shifting risk factor profiles
🔹 AI tools for personalised care

doi.org/10.1093/eurh...
2 4 5
Reposted by Simon Kraler
nejm.org
NEJM.org @nejm.org · May 3
Lepodisiran is a long-acting small interfering RNA that blocks hepatic apolipoprotein(a) production. A new Quick Take video covers the ALPACA trial’s findings in patients with elevated lipoprotein(a).

🎥 Watch now: youtu.be/B0aH0O9Pk7Q

#MedSky #CardioSky
Lepodisiran: an RNA Targeting Lipoprotein(a) (ALPACA trial) | NEJM
YouTube video by NEJM Group
youtu.be
6 8